Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Moving Today?

Rapport Therapeutics shares rose 11.60% to $25.11 on Wednesday, reversing a recent decline following the pricing of a substantial capital raise. The move came after the company announced underwritten offerings of common stock, pre-funded warrants, and convertible notes.

What Happened

Rapport Therapeutics announced the pricing of separate offerings totaling approximately $350 million. The package includes roughly $175 million of common stock priced at $21.00 per share, warrants to purchase up to $25 million of stock at $20.999 per pre-funded warrant, and $150 million of 2.25% convertible senior notes due 2032. A concurrent private placement was also part of the transaction. The stock had previously slid 22.5% in pre-market trading on October 28 amid uncertainty over the fundraising.

Recent insider activity provided a counterpoint to the dilution concerns. Three directors, Ramiro Sanchez, John Maraganore, and Paul M. Silva, purchased shares in late October. These transactions were part of a broader trend where six buys totaling $1.7 million occurred over the last 90 days, compared to nine sells totaling $6.9 million.

What The Data Shows

The stock opened at $22.62, a 0.5% gap from the prior close of $22.50. It reached a session high of $25.17 at 11:05 AM ET and a low of $22.51 at 7:30 AM ET. Volume stood at 0.6 million shares, which is 1.2 times the three-month daily average. The company has a market capitalization of $1.3 billion and is unprofitable with a trailing twelve-month EPS of -$3.05. The 52-week range is $22.06 to $52.93. Over the last eight sessions, the stock had fallen 21.3% from $28.60 to $22.50. The 52-week tape recorded 21 fresh highs on October 29, 2026.

What To Watch

Investors will monitor the execution of the capital raise and its impact on the company's clinical pipeline. The recent insider buying by directors may signal confidence in the long-term value despite the immediate dilution from the new securities offerings.